Stockreport

Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis

Lyra Therapeutics, Inc.  (LYRA) 
PDF Single primary endpoint defined as three cardinal symptoms at 24 weeksCompany to host conference call at 5:00 PM ET today WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Ther [Read more]